株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

プラダー・ウィリー症候群 (PWS) 治療薬の世界市場:市場機会と将来予測

Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 - 2024)

発行 Azoth Analytics 商品コード 913190
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
プラダー・ウィリー症候群 (PWS) 治療薬の世界市場:市場機会と将来予測 Global Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 - 2024)
出版日: 2019年09月30日 ページ情報: 英文 120 Pages
概要

当レポートでは、世界のプラダー・ウィリー症候群 (PWS) 治療薬の市場について分析し、疾患の概要や主な治療法、現在治験中の有望なパイプライン製品、有病者数および市場収益額の動向見通し (過去2年間・今後6年間分)、地域別の詳細動向、市場促進・抑制要因、市場の求心力、主要企業のプロファイルなどを調査しております。

第1章 分析手法

第2章 エグゼクティブ・サマリー

第3章 戦略提言

  • ソマトロピン・バイオシミラー向け投資
  • プラダー・ウィリー症候群 (PWS) 向け併用療法への投資

第4章 手術用マスク市場:製品別の将来展望

第5章 世界のプラダー・ウィリー症候群 (PWS) 治療薬市場:成長率と将来予測

  • 市場規模:実績値 (金額ベース、過去2年間分)
  • 市場規模:予測値 (金額ベース、今後6年間分)

第6章 世界のPWS治療薬市場:パイプライン分析

  • パイプライン分析:DCCR
  • パイプライン分析:Levolitide
  • パイプライン分析:Tesomet

第7章 世界のPWS治療薬市場:地域別分析

第8章 米国のPWS治療薬市場

  • 市場規模 (通算8年間分)
  • 有病者数 (通算8年間分)

第9章 欧州のPWS治療薬市場

第10章 日本のPWS治療薬市場

第11章 競争環境

第12章 製品間の相互比較

第13章 市場のダイナミクス

  • 市場促進要因
  • 市場抑制要因
  • 市場動向

第14章 ポーターのファイブフォース分析

第15章 SWOT分析

第16章 規制体制

第17章 企業プロファイル

  • Pfizer
  • Novartis AG
  • Novo Nordisk
  • Soleno Therapeutics
  • Saniona
図表

List of Figures

  • Figure 1: Global Prader-Willi Syndrome Market Size, By Value, 2017-2018 (USD Million)
  • Figure 2: Global Prader-Willi Syndrome Market Size, By Value, 2019F-2024F (USD Million)
  • Figure 3: Global Genotropin Sales, 2014-2014
  • Figure 4: Global Norditropin Sales, 2014-2014
  • Figure 5: Causes of Mortality in PWS Patients
  • Figure 6: Expected Global Medical Spending in 2020, By Product Type, (% of Total)
  • Figure 7: Expected Global Medical Spending in 2020, By Region, (% of Total)
  • Figure 8: Global Life Expectancy At Birth For Selected Periods
  • Figure 9: Life Expectancy at Birth For Selected Periods, By Region
  • Figure 10: Projected global population (In Billions)
  • Figure 11: Projected global population aged 60 years & above (In Billions)
  • Figure 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
  • Figure 13: Healthcare Expenditure (Share of GDP), By Select Country, 2013-2018 (In %)
  • Figure 14: Global Expected Healthcare Industry Outlook
  • Figure 15: Regional Expected Healthcare Industry Growth Rate By Year 2020
  • Figure 16: DCCR, Clinical Study Status
  • Figure 17: DCCR, Estimated US Market Value, According to Price and Penetration Rate, In USD Million
  • Figure 18: DCCR, Mean US Market Value, By Price and Penetration Rate, In USD Million
  • Figure 19: Livoletide, Clinical Study Status
  • Figure 20: Livoletide, Estimated US Market Value, In USD Million
  • Figure 21: Livoletide, Estimated US Cost Per Patient Annually, In USD Million
  • Figure 22: Tesomet, Clinical Study Status
  • Figure 23: Tesomet Timeline For PWS
  • Figure 24: Tesomet , US Expected Sales
  • Figure 25: Tesomet , US Expected Sales
  • Figure 26: Global Prader-Willi Syndrome Market Size, By Region, 2018, (%)
  • Figure 27: Global Prader-Willi Syndrome Market Size, By Region, 2024, (%)
  • Figure 28: USA Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
  • Figure 29: USA Prader-Willi Syndrome Prevalence, 2017-2024E
  • Figure 30: Mean Total Care Costs of Patients with PWS and Matched Controls
  • Figure 31: PWA (USA) Funds Split
  • Figure 32: United States Per Capita Spending on Medicines, 2013-2017 (In USD)
  • Figure 33: Medical and Healthcare Research & Development Spending, 2013-2018 (In USD Billion)
  • Figure 34: U.S., Per Capita Expenditure on Healthcare, 2012-2018 (In USD)
  • Figure 35: Europe Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
  • Figure 36: Europe Prader-Willi Syndrome Prevalence, 2017-2024E
  • Figure 37: Europe Union, Proportion of population aged 65 and over, 2014-2018 (% of Total Population)
  • Figure 38: Europe, Per Capita Health Expenditure, By Select Country, 2017 (USD)
  • Figure 39: GDP (Current USD), Europe Region, By Select Country, 2014-2018 (In Trillion USD)
  • Figure 40: Germany, Federal Government R&D Spending, 2017
  • Figure 41: Germany, Government R&D Spending on Health Research and Industry, (Euro Million), 2017
  • Figure 42: Germany, Spending on Healthcare, 2015 & 2040E, (USD Per Person)
  • Figure 43: France, Health Infrastructure, 2017
  • Figure 44: France, Healthcare Infrastructure Related Statistics
  • Figure 45: France, Spending on Healthcare, 2015 & 2040,(USD Per Person)
  • Figure 46: U.K, Health Expenditure, (% of GDP), 2014-2017 (USD)
  • Figure 47: U.K, Spending on Healthcare, 2015 & 2040, (USD Per Person)
  • Figure 48: Japan Prader-Willi Syndrome Market Size, By Value, 2017-2024E (USD Million)
  • Figure 49: Japan Prader-Willi Syndrome Prevalence, 2017-2024E
  • Figure 50: Japan Healthcare Expenditure Outlook (%)
  • Figure 51: Japan, Population, 2014-2017
  • Figure 52: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 53: Japan, Population ages 65 and above, 2012-2018 (% of total)
  • Figure 54: Japan, GDP Growth Per Year, 2015-2019F (In %)
  • Figure 55: Japan, Population ages 65 and above, 2012-2018 (% of total)
  • Figure 56: Pfizer, Net Sales, 2014-2018 (USD Million)
  • Figure 57: Pfizer, Revenue, By Segments, 2018 (%)
  • Figure 58: Pfizer, Revenue, By Region, 2018 (%)
  • Figure 59: Novartis, Net Sales, 2013-2017 (USD Million)
  • Figure 60: Novartis, Revenue, By Segment, 2018(%)
  • Figure 61: Novartis, Revenue, By Region, 2018(%)
  • Figure 62: Novo Nordisk, Net Sales, 2014-2018 (In Million USD)
  • Figure 63: Novo Nordisk, Net Sales, By Business Sector, 2018 (In %)
  • Figure 64: Novo Nordisk, Net Sales, By Geographic Region, 2018 (In %)
  • Figure 65: Saniona, Net Sales, 2014-2018 (In Million USD)
  • Figure 66: Saniona, Drugs in Development, 2018

List of Tables

  • Table A: Somatropin Biosimilars For GHD and PWS
  • Table B: Genetic Therapies In Development For Prader-Willi Syndrome
  • Table C: Hyperphagia / Obesity Drugs In Development For Prader-Willi Syndrome
  • Table D: Behavior and Appetite Drugs In Development For Prader-Willi Syndrome
  • Table E: Muscle Development Therapies In Development For Prader-Willi Syndrome
  • Table F: PWS Mean Age Of Death, By Cause
  • Table G: Rare Disease Definitions Across Geographic Regions
  • Table H: DCCR, Trail Details
  • Table I: DCCR, US Market Analysis
  • Table J: Livoletide, Trail Details
  • Table K: Livoletide, US Market Analysis
  • Table L: Tesomet Trail Details
  • Table M: Tesomet , US Market Analysis
  • Table N: Tesomet , EU Market Analysis
  • Table O: Unites States, Hospitals Related Statistics, In 2018
  • Table P: Unites States, Number of Leading Drug Stores, In 2017
  • Table Q: Europe, Availability of Somatropin, By Country
  • Table R: EU-5 Socio-Economical Statistics, 2018
  • Table S: Germany, Hospitals Relates Statistics, 2017
  • Table T: Germany, Number of leading drug store chain, 2018
  • Table U: Germany, Pharmacies Related Statistics, 2017
  • Table V: Japan Healthcare System Outlook, 2017
  • Table W: Competitive Landscape of Selected Drugs In Development
  • Table X: Human Growth Hormone Products For PWS, By Company
目次

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Prader-Willi Syndrome market. The report analyses the Global Prader-Willi Syndrome Therapeutics Market in terms of its sizing, growth and forecast. The report presents a comprehensive pipeline assessment that includes DCCR (Soleno Therapeutics), Levolitide (Millendo Therapeutics) and Tesomet (Saniona). Also, the report analyzes the prevalence of PWS and profiles the leading companies operating in the PWS Therapeutics market. The report analyzes the Global Market, European Region Market and the country analysis of United States and Japan for the historical period of 2017 and 2018 and the forecast period of 2019-2024.

According to Azoth Analytics research report, the Prader-Willi Syndrome therapeutics market is projected to display a robust growth represented by a CAGR of 4.6% during 2019 - 2024.

Over the recent years, the Prader-Willi Syndrome market has been witnessing considerable growth directly on the back of the increasing number of diagnosed patient's population. Moreover, growing human growth hormone therapy coverage rate, surging awareness and increasing government involvement have been driving the market.

Further, expected launch of novel therapies, such as DCCR (Soleno Therapeutics), Livoletide (Millendo Therapeutics), Testomet (Saniona AB) among others are anticipated to fuel the market growth.

The report titled report "Prader-Willi Syndrome (PWS) Therapeutics Market: Sizing, Prevalence, Pipeline Analysis (2019 Edition): Opportunities and Forecast (2019 - 2024)" has covered and analyzed the potential of Prader-Willi Syndrome market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges, opportunities and market entry strategies for various companies. Additionally, the report also highlights the estimated prevalence of Prader-Willi Syndrome in USA, Europe and Japan.

Scope of the Report

Global Prader-Willi Syndrome Market (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Prader-Willi Syndrome Market - Size, Growth, Forecast
  • Prader-Willi Syndrome Market: Pipeline Analysis
    • DCCR (Soleno Therapeutics)
    • Levolitide (Millendo Therapeutics)
    • Tesomet (Saniona)

Regional Prader-Willi Syndrome Market - U.S.A, Europe, Japan (Actual Period: 2017-2018, Forecast Period: 2019-2024)

  • Prader-Willi Syndrome Market - Size, Growth, Forecast
  • Prader-Willi Syndrome Market: Pipeline Analysis
    • DCCR (Soleno Therapeutics)
    • Levolitide (Millendo Therapeutics)
    • Tesomet (Saniona)

Other Report Highlights

  • Pipeline Analysis.
  • Competitive Landscape.
  • Product Benchmarking.
  • Market Dynamics - Drivers and Restraints.
  • Market Trends.
  • Porter Five Forces Analysis.
  • SWOT Analysis.
  • Company Analysis - Pfizer, Novartis, Novo Nordisk, Soleno Therapeutics, Saniona

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

  • 3.1 Invest in Somatropin Biosimilar
  • 3.2 Invest in Combination Therapy For PWS

4. Surgical Masks Product Outlook

5. Global Prader-Willi Syndrome Market: Growth and Forecast

  • 5.1 By Value (2017-2018)
  • 5.2 By Value (2019-2024)

6. Global Prader-Willi Syndrome Pipeline Analysis

  • 6.1 DCCR Pipeline Analysis
  • 6.2 Levolitide Pipeline Analysis
  • 6.3 Tesomet Pipeline Analysis

7. Global Prader-Willi Syndrome Market, By Region

8. U.S.A Prader-Willi Syndrome Market

  • 8.1 U.S.A Prader-Willi Syndrome Market Size (2017-2024F)
  • 8.2 U.S.A Prader-Willi Syndrome Prevalence (2017-2024F)

9. Europe Prader-Willi Syndrome Market

  • 9.1 Europe Prader-Willi Syndrome Market Size (2017-2024F)
  • 9.2 Europe Prader-Willi Syndrome Prevalence (2017-2024F)

10. Japan Prader-Willi Syndrome Market

  • 10.1 Japan Prader-Willi Syndrome Market Size (2017-2024F)
  • 10.2 Japan Prader-Willi Syndrome Prevalence (2017-2024F)

11. Global Prader-Willi Syndrome Market - Competitive Landscape

12. Global Prader-Willi Syndrome Market - Product Benchmarking

13. Global Prader-Willi Syndrome Market: Market Dynamics

  • 13.1 Global Prader-Willi Syndrome Market Drivers
  • 13.2 Global Prader-Willi Syndrome Market Restrains
  • 13.3 Global Prader-Willi Syndrome Market Trends

14. Porter Five Force Analysis

15. SWOT Analysis

16. Global Prader-Willi Syndrome Market: Regulatory Frameworks

17. Company Profiles

  • 17.1 Pfizer
  • 17.2 Novartis AG
  • 17.3 Novo Nordisk
  • 17.4 Soleno Therapeutics
  • 17.4 Saniona
Back to Top